Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | MYC | P01106 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | ATIC | P31939 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15216504 | 1.00 | KMT2A (0.38) | KMT2AALDH1A1MEN1TDP1MYC | |
| SCHEMBL29514984 | 1.00 | KMT2A (0.38) | KMT2AALDH1A1MEN1TDP1MYC | |
| SCHEMBL6449477 | 0.98 | KMT2A (0.38) | KMT2AALDH1A1MEN1TDP1MYC | |
| SCHEMBL29136456 | 0.93 | TDP1 (0.46) | KMT2AALDH1A1MEN1TDP1MYC | |
| SCHEMBL2799147 | 0.85 | KMT2A (0.36) | KMT2AALDH1A1MEN1TDP1TSHR | |
| SCHEMBL13232732 | 0.85 | KMT2A (0.36) | KMT2AALDH1A1MEN1TDP1TSHR | |
| SCHEMBL6449468 | 0.83 | KMT2A (0.38) | KMT2AALDH1A1MEN1TDP1THRB | |
| SCHEMBL13232749 | 0.83 | CA2 (0.40) | KMT2AALDH1A1MEN1CYP2C9CA1 | |
| SCHEMBL13233049 | 0.82 | PSIP1 (0.36) | KMT2AALDH1A1MEN1TDP1CYP1A2 | |
| SCHEMBL2800278 | 0.82 | PSIP1 (0.36) | KMT2AALDH1A1MEN1TDP1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11946066-B2 | RNA-based delivery systems with levels of control | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2024-04-02 | — | — | US | claimed |
| US-20230193317-A1 | RNA-BASED DELIVERY SYSTEMS WITH LEVELS OF CONTROL | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2023-06-22 | — | — | US | claimed |
| US-11453893-B2 | RNA-based delivery systems with levels of control | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-09-27 | — | — | US | claimed |
| US-20050272724-A1 | Spin trapping pharmaceutical compositions and methods for use thereof | CARNEY JOHN M | 2005-12-08 | — | — | US | claimed |
| US-6815425-B1 | ADMINISTERED WITH N-TERT-BUTYL- ALPHA -(2-SULFOPHENYL)NITRONE (SPBN); NEUROPROTECTANTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2004-11-09 | — | — | US | claimed |
| US-6339102-B1 | Method and composition for treating and preventing retinal damage | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2002-01-15 | — | — | US | claimed |
| WO-2001028578-A2 | A PHARMACEUTICAL COMPOSITION CONTAINING pGLU-GLU-PRO-NH2 AND METHOD FOR TREATING DISEASES AND INJURIES TO THE BRAIN, SPINAL CORD AND RETINA USING SAME | WRAIR (US) | 2001-04-26 | — | — | WO | claimed |
| WO-2000074672-A1 | METHOD AND COMPOSITIONS FOR TREATING AND PREVENTING RETINAL DAMAGE | DEPARTMENT OF THE ARMY, U.S. GOVERNMENT (US) | 2000-12-14 | — | — | WO | claimed |
| US-5622994-A | NITRONE DERIVATIVES | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 1997-04-22 | — | — | US | claimed |
| US-20250270262-A1 | METHOD FOR ROBUST CONTROL OF GENE EXPRESSION | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2025-08-28 | — | — | US | disclosed |
| US-12297236-B2 | Method for robust control of gene expression | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2025-05-13 | — | — | US | disclosed |
| US-20250134991-A1 | MONOPHOSPHORYL LIPID ADJUVANT (MPLA) COMPOSITIONS, VACCINE COMPOSITIONS THEREOF, AND METHODS OF PREPARING AND USING THE SAME | UNIV JEFFERSON (US) | 2025-05-01 | — | — | US | disclosed |
| CN-119862602-A | Data verification method, device, equipment and medium | 建信金融科技有限责任公司 | 2025-04-22 | — | — | CN | disclosed |
| US-12269155-B2 | Multivalent vaccines for rabies virus and coronaviruses | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-04-08 | — | — | US | disclosed |
| EP-0736004-A1 | 2,4-DISULFONYL PHENYL BUTYL NITRONE, ITS SALTS, AND THEIR USE AS PHARMACEUTICALS | Oklahoma Medical Research Foundation (US) | 1996-10-09 | — | — | EP | disclosed |
| US-5508305-A | 2, 4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceuticals | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 1996-04-16 | — | — | US | disclosed |
| US-5488145-A | 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 1996-01-30 | — | — | US | disclosed |
| US-5475032-A | Treating strokes | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 1995-12-12 | — | — | US | disclosed |
| WO-1995017876-A2 | 2,4-DISULPHOPHENYL BUTYLNITRONE, ITS SALTS, AND THEIR USE AS PHARMACEUTICAL SPINTRAPS | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 1995-07-06 | — | — | WO | disclosed |
| EP-0590072-A1 | USE OF SPIN TRAPPING FOR THE TREATMENT OF DISEASES ASSOCIATED WITH OXIDATION OF LIPIDS AND PROTEINS | Oklahoma Medical Research Foundation (US) | 1994-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272724-A1 | Spin trapping pharmaceutical compositions and methods for use thereof | PPOX, TXN2, TXN | KMT2A 4082/4885ALDH1A1 2407/4885MEN1 2645/4885 |
| US-20250134991-A1 | MONOPHOSPHORYL LIPID ADJUVANT (MPLA) COMPOSITIONS, VACCINE COMPOSITIONS THEREOF, AND METHODS OF PREPARING AND USING THE SAME | SQLE, MPL, FDFT1 | KMT2A 1813/4885ALDH1A1 4311/4885MEN1 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.